The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 25, Issue 3, 2011, Pages 469-478

  Paik, Il Joon ^a   Kotler, Donald P ^b  

^a Columbia University ^*  (United States)

^b Department of Darmatology   (United States)

Author keywords

diabetes mellitus; HIV infection; insulin resistance; mitochondrial dysfunction; nucleoside reverse transcriptase inhibitors; protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INSULIN RESISTANCE; METABOLIC DISORDER; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE;

EID: 79958281980     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2011.04.003     Document Type: Review

References (85)

1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the expert committee on the diagnosis and classification of diabetes mellitus Diabetes Care 25 2002 S5 S20
2. International Diabetes Federation Prevalence data in 2010 Available at August 25, 2010 http://atlas.idf-bxl.org/content/prevalence-estimates-diabetes- mellitus-dm-2010 Accessed
3. T.T. Brown, X. Li, and S.R. Cole Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the multicenter AIDS cohort study Acquired Immune Deficiency Syndrome 19 2005 1375 1383 (Pubitemid 41800673)
4. V. Estrada, M.T. Martinez-Larrad, and J.L. Gonzalez-Sanchez Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy Metabolism 55 2006 940 945 (Pubitemid 43902897)
5. K. Samaras, H. Wand, and M. Law Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using international diabetes foundation and adult treatment panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia Diabetes Care 30 2007 113 119 (Pubitemid 46052508)
6. S. Grinspoon Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome Clinical Infectious Disease 2 37 Suppl. 2003 S85 S90
7. C. Hadigan, J.B. Meigs, and C. Corcoran Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy Clinical Infectious Disease 32 2001 130 139 (Pubitemid 32150958)
8. W.M. El-Sadr, C.M. Mullin, and A. Carr Effects of HIV disease on lipid, glucose and insulin level: results from a large antiretroviral-naïve cohort HIV Medicine 6 2005 114 121 (Pubitemid 40425975)
9. T.T. Brown, S.R. Cole, and X. Li Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study Archives of Internal Medicine 165 2005 1179 1184 (Pubitemid 40720744)
10. M. Beregszaszi, C. Dollfus, and M. Levine Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children Journal of Acquired Immune Deficiency Syndrome 40 2005 161 168 (Pubitemid 41395714)
11. R. Palacios, N. Merchante, and J. Macias Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy Antiviral Therapy 11 4 2006 529 535 (Pubitemid 44024861)
12. P.C. Tien, M.F. Schneider, and S.R. Cole Antiretroviral therapy exposure and incidence of diabetes mellitus in the women's interagency HIV Study Acquired Immune Deficiency Syndrome 21 13 2007 Aug 20 1739 1745 (Pubitemid 47237561)
13. M.C. Gelato Insulin and carbohydrate dysregulation Clinical Infectious Disease 36 Suppl. 2 2003 S91 S95
14. A. Carr, K. Samaras, and A. Thorisdottir Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study Lancet 353 1999 2093 2099 (Pubitemid 29278477)
15. J.A. Eastone, and C.F. Decker New-onset diabetes mellitus associated with use of protease inhibitor Annals of Internal Medicine 127 1997 948 (Pubitemid 27490630)
16. S. De Witt, C.A. Sabin, and R. Weber Incidence and risk factors for new-onset diabetes in HIV-infected patients: the data collection on adverse events of anti-HIV drugs (D:A:D) study Diabetes Care 31 2008 1224 1229
17. D.A. Wohl, G. McComsey, and P. Tebas Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy Clinical Infectious Disease 43 2006 645 653 (Pubitemid 44267129)
18. J.S. Currier, and D.V. Havlir Complications of HIV disease and antiretroviral therapy Top HIV Medicine 12 2004 31 45
19. M.J. Hommes, J.A. Romijn, and E. Endert Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men Metabolism 40 1991 651 656
20. C. Hadigan, C. Corcoran, and T. Stanley Fasting hyperinsulinemia in human immunodeficiency virus- infected men: relationship to body composition, gonadal function, and protease inhibitor use Journal of Clinical Endocrinology and Metabolism 85 2000 35 41 (Pubitemid 32268786)
21. C. Hadigan, S. Borgonha, and J. Rabe Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy Metabolism 51 2002 1143 1147
22. K. Brinkman, J.A. Smeitink, and J.A. Romijn Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the patho- genesis of antiretroviral-therapy-related lipodystrophy Lancet 354 1999 1112 1115 (Pubitemid 29452832)
23. W. Lewis, B.J. Day, and W.C. Copeland Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective Nature Reviews Drug Discovery 2 2003 812 822 (Pubitemid 37361813)
24. M. Gerschenson, and K. Brinkman Mitochondrial dysfunction in AIDS and its treatment Mitochondrion 4 2004 763 777 (Pubitemid 39646821)
25. K. Muthumani, A.Y. Choo, and D.S. Hwang Mechanism of HIV-1 viral protein R-induced apoptosis Biochemical and Biophysical Research Communications 304 2003 583 592 (Pubitemid 36506531)
26. D. Arnoult, F. Petit, and J.D. Lelievre Mitochondria in HIV-1-induced apoptosis Biochemical and Biophysical Research Communications 304 2003 561 574 (Pubitemid 36506529)
27. M. Caron, M. Auclair, and C. Lagathu The HIV-1 nucleo- side reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro Acquired Immune Deficiency Syndrome 18 2004 2127 2136 (Pubitemid 39463677)
28. Ranade K, Parker R, Ploughman L et al. A single nucleotide polymorphism in the resistin gene is associated with adverse metabolic changes on HAART: an exploratory pharmacogenetic association study of A5005s, the metabolic sub-study of ACTG 384. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, USA. Abstract 763.
29. K. Morino, K.F. Petersen, and S. Dufour Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents Journal of Clinical Investigation 115 2005 3587 3593 (Pubitemid 43121847)
30. A. Carr, K. Samaras, and S. Burton A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving protease inhibitors Acquired Immune Deficiency Syndrome 12 1998 F51 F58
31. H. Murata, P.W. Hruz, and M. Mueckler The mechanism of insulin resistance caused by HIV protease inhibitor therapy Journal of Biological Chemistry 275 2000 20251 20254 (Pubitemid 30457596)
32. M.A. Noor, J.C. Lo, and K. Mulligan Metabolic effects of indinavir in healthy HIV-seronegative men Acquired Immune Deficiency Syndrome 15 2001 F11 F18
33. M.A. Noor, T. Seneviratne, and F.T. Aweeka Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study Acquired Immune Deficiency Syndrome 16 2002 F1 F8
34. M.A. Noor, R.A. Parker, and E. O'Mara The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults Acquired Immune Deficiency Syndrome 18 2004 2137 2144 (Pubitemid 39463678)
35. M. Noor, O.P. Flint, and R.A. Parker Evaluation of insulin sensitivity in healthy volunteers treated with low-dose ritonavir combined with atazanavir (ATV/RTV) or lopinavir (LPV/RTV): a prospective, randomized study using hyperinsulinaemic, euglycaemic clamp and oral glucose tolerance testing Antiviral Therapy 10 Suppl. 3 2005 L11 (Abstract 16)
36. G. Lee, M.N. Rao, and J.M. Schwarz A single dose of amprenavir does not induce insulin resistance in healthy normal volunteers Antiviral Therapy 10 Suppl. 3 2005 L11 (Abstract 15)
37. G.A. Lee, D.D. Mafong, and M.A. Noor HIV protease inhibitors increase adiponectin levels in HIV-negative men Journal of Acquired Immune Deficiency Syndrome 36 2004 645 647 (Pubitemid 38552377)
38. M.P. Dube, D. Qian, and H. Edmondson-Melancon Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy Clinical Infectious Disease 35 2002 475 481 (Pubitemid 34852578)
39. Shahmanesh M, Das S, Stolinski M et al. Insulin Resistance and apolipoprotein B kinetics: a comparison of protease inhibitor-, Efavirenz-, or Nevirapine-containing antiretroviral regimens. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, USA. Abstract 704.
40. Cooper D, Gatell J, Rockstroh J et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1integrase inhibitor, in patients with triple-class resistant virus. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 105aLB.
41. Steigbigel R, Kumar P, Eron J et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1integrase inhibitor, in patients with triple-class resistant virus. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 105bLB.
42. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of phase 2b/3 studies. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA.
43. P. Randell, A. Jackson, and K. Dennis The impact of raltegravir and lopinavir/ritonavir on peripheral glucose disposal in HIV-negative men Antiviral Therapy 13 Suppl. 4 2008 A18
44. P. Randell, A. Jackson, and L. Zhong The impact of tenofovir disoproxil fumarate on insulin sensitivity, adipocytokines and markers of endothelial function Antiviral Therapy 13 suppl. 4 2008 A29
45. P. Limone, A. Biglino, and M. Valle Insulin resistance in HIV-infected patients: relationship with pro-inflammatory cytokines released by peripheral leukocytes Journal of Infection 47 2003 52 58 (Pubitemid 36850136)
46. Shrivastav S, Kino T, Chrousos GP, Kopp JB HIV-1 Vpr binds and inhibits PPAR-γ: implications for HIV-associated insulin resistance and lipodystrophy. Presented at the International Meeting of the Institute of Human Virology, Baltimore, MD, 2000
47. Kino T, Gragerov A, Pavlakis GN, Chrousos GP, HIV-1 accessory protein Vpr antagonizes insulin's effect on the cytosolic translocation of FKHR and promotes its transcriptional activity: potential contribution of Vpr to insulin resistance of AIDS patients. Program of the 83rd Annual Meeting of The Endocrine Society, Denver, CO, 2001, p 95 (Abstract OR20-4).
48. G.S. Hotamisligil, D.L. Murray, and L.N. Choy TNF-α inhibits signaling from the insulin receptor Proceedings of the National Academy of Sciences USA 91 1994 4854 4858 (Pubitemid 24177748)
49. G.S. Hotamisligil, P. Peraldi, and A. Budavari IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance Science 271 1996 665 668 (Pubitemid 26052915)
50. J.M. Stephens, J. Lee, and P.F. Pilch Tumor necrosis factor-α- induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction Journal of Biological Chemistry 272 1997 971 997
51. F.B. Hu, J.B. Meigs, and T.Y. Li Inflammatory markers and risk of developing type 2 diabetes in women Diabetes 53 3 2004 Mar 693 700 (Pubitemid 38270639)
52. J. Spranger, A. Kroke, and M. Mohlig Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-Potsdam study Diabetes 52 3 2003 Mar 812 817 (Pubitemid 36323590)
53. S. Liu, L. Tinker, and Y. Song A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women Archives of Internal Medicine 167 15 2007 Aug 13 1676 1685 (Pubitemid 47280350)
54. T.T. Brown, K. Tassiopoulos, and R.J. Bosch Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy Diabetes Care 33 10 2010 Oct 2244 2249 Epub 2010 Jul 27
55. R. Simo, C. Hernandez, and J. Genesca High prevalence of hepatitis C virus infection in diabetic patients Diabetes Care 19 1996 998 1000 (Pubitemid 26301238)
56. A.L. Mason, J.Y. Lau, and N. Hoang Association of diabetes mellitus and chronic hepatitis C virus infection Hepatology 29 1999 328 333 (Pubitemid 29088433)
57. H. Knobler, R. Schihmanter, and A. Zifroni Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection Mayo Clinic Proceedings 75 2000 355 359 (Pubitemid 30187108)
58. G.F. De Larranaga, S.D. Wingeyer, and L.M. Puga Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment European Journal of Clinical Microbiology and Infectious Disease 25 2006 98 103 (Pubitemid 43333670)
59. S.H. Mehta, R.D. Moore, and D.L. Thomas The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons Journal of Acquired Immune Deficiency Syndrome 33 2003 577 584 (Pubitemid 36975845)
60. M. Duong, J.M. Petit, and L. Piroth Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing anti-retroviral therapy Journal of Acquired Immune Deficiency Syndrome 27 2001 245 250 (Pubitemid 32661965)
61. M.K. Jain, C. Aragaki, and L. Fischbach Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors HIV Medicine 8 2007 491 497 (Pubitemid 47616827)
62. K. Henry, H. Melroe, and J. Huebsch Severe premature coronary disease with protease inhibitors Lancet 351 1998 1328 1329
63. S.M. Haffner, S. Lehto, and T. Rönnemaa Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction New England Journal of Medicine 339 1998 229 234 (Pubitemid 28350165)
64. S.W. Worm, S. De Wit, and R. Weber Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the data collection on adverse events of anti-HIV drugs (D:A:D Study) Circulation 119 2009 805 811
65. S.W. Worm, C. Sabin, and R. Weber Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study Journal of Infectious Disease 201 3 2010 Feb 1 318 330
66. M. Schambelan, C.A. Benson, and A. Carr Management of metabolic complications associated with antiretroviral therapy for HIV-1infection: recommendations of an international AIDS society-USA panel Journal of Acquired Immune Deficiency Syndrome 33 2002 257 275 (Pubitemid 35278626)
67. American Diabetes Association Standards of medical care of patients with diabetes mellitus Diabetes Care 23 Suppl. 1 2000 S32 S42
68. A. Gavrila, S. Tsiodras, and J. Doweiko Exercise and vitamin E intake are independently associated with metabolic abnormalities in human immunodeficiency virus-positive subjects: a cross-sectional study Clinical Infectious Disease 36 2003 1593 1601 (Pubitemid 36783345)
69. K.E. Yarasheski, P. Tebas, and B. Stanerson Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy Journal of Applied Physiology 90 2001 133 138 (Pubitemid 32038513)
70. K.V. Fitch, E.J. Anderson, and J.L. Hubbard Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome Acquired Immune Deficiency Syndrome 20 14 2006 Sep 11 1843 1850 (Pubitemid 44358902)
71. E.S. Engelson, D. Agin, and S. Kenya Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women Metabolism 55 10 2006 Oct 1327 1336 (Pubitemid 44354946)
72. J.B. Albu, C.M. Kim, and E.S. Engelson Effects of diet and exercise and/or rosiglitazone on body composition and glucose metabolism in HIV+ and HIV- subjects Antiviral Therapy 13 Suppl. 4 2008 A31
73. S.D. Driscoll, G.E. Meininger, and M.T. Lareau Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients Acquired Immune Deficiency Syndrome 18 2004 465 473 (Pubitemid 38365874)
74. C. Hadigan, C. Corcoran, and N. Basgoz Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial Journal of the American Medical Association 284 2000 472 477 (Pubitemid 30484481)
75. C. Hadigan, J.B. Meigs, and J. Rabe Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance Journal of Clinical Endocrinology and Metabolism 86 2001 939 943 (Pubitemid 32207521)
76. T. Saint-Marc, and J.L. Touraine Effects of metformin on insulin resistance and central adiposity in patients receiving effec- tive protease inhibitor therapy Acquired Immune Deficiency Syndrome 13 1999 1000 1002 (Pubitemid 29240202)
77. S. Schwartz, P. Raskin, and V. Fonseca Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and exogenous insulin study group New England Journal of Medicine 338 1998 861 866 (Pubitemid 28135962)
78. S.E. Inzucchi, D.G. Maggs, and G.R. Spollett Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus New England Journal of Medicine 338 1998 867 872 (Pubitemid 28135963)
79. P. Tontonoz, E. Hu, and B.M. Spiegelman Stimulation of adipogenesis in fibroblasts by PPAR-g 2, a lipid-activated transcription factor Cell 79 1994 1147 1156
80. E. Arioglu, J. Duncan-Morin, and N. Sebring Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes Annals of Internal Medicine 133 2000 263 274 (Pubitemid 30660298)
81. C. Hadigan, S. Yawetz, and A. Thomas Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial Annals of Internal Medicine 140 2004 786 794
82. A. Carr, C. Workman, and D. Carey No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial Lancet 363 2004 429 438 (Pubitemid 38210059)
83. J. Sutinen, A.M. Hakkinen, and J. Westerbacka Rosiglitazone in the treatment of HAART-associated lipodystrophy- - a randomized double-blind placebo- controlled study Antiviral Therapy 8 2003 199 207 (Pubitemid 36960893)
84. H. Yki-Jarvinen, J. Sutinen, and A. Silveira Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy Arteriosclerosis Thrombosis and Vascular Biology 23 2003 688 694 (Pubitemid 36438085)
85. S.M. Grundy, B. Hansen, and S.C. Smith Jr. Clinical management of metabolic syndrome: report of the American heart association/national heart, lung, and blood institute/American diabetes association conference on scientific issues related to management Arteriosclerosis Thrombosis and Vascular Biology 24 2004 e19 e24